BCL2L1 and plasma cell myeloma: Finally, in multiple myeloma, using the dataset reported by Agnelli and Co. [92], in the analysis of the expression of BCL-xL according to the stage of the myeloma, a discrete but important increase in the expression of BCL-xL is found according to a more advanced stage (Figure 13A), which could suggest that the protein participates in the aggressiveness of the disease.